Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2005-11-29
2005-11-29
Housel, James (Department: 1648)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S365100, C435S320100, C435S360000, C435S362000, C435S372000, C435S372100, C435S374000, C435S375000, C435S377000, C435S376000, C435S366000, C435S385000, C435S386000, C424S093100, C424S009100, C424S085100
Reexamination Certificate
active
06969609
ABSTRACT:
The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of them costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater that the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+and CD8+T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced and antigen-presenting functions.
REFERENCES:
patent: 5185146 (1993-02-01), Altenburger
patent: 5738852 (1998-04-01), Robinson et al.
patent: 6045802 (2000-04-01), Schlom et al.
patent: 6440422 (2002-08-01), Sutter et al.
patent: 6548068 (2003-04-01), Schlom et al.
patent: 0 803 573 (1996-04-01), None
patent: 0733 373 (1996-09-01), None
patent: WO 9610419 (1996-04-01), None
patent: WO097/00085 (1997-01-01), None
patent: WO 9804727 (1998-02-01), None
Zajac et al. Cancer Research, Oct. 1998, vol. 58, pp. 4567-4571.
Oertli et al. J. Gene. Virol. vol. 77, pp. 3121-3125.
Parra et al. Scand. J. Immunol. 1993, vol. 38, pp. 508-514.
Goldbach-Mansky et al. Int J. Immunol. 1992, vol. 4, pp. 1315-1360.
Young et al. J. Clin. Invest. 1992, vol. 90, pp. 229-237.
Radmyr et al. Int. J. Cancer 1995, vol. 63, pp. 627-632.
Delable et al. Leuk. Lymphoma 1995, vol. 18, pp. 35-40.
Wyss-Coray et al. Eur. J. Immunol. 1993, vol. 23, pp. 3350-3357.
Vyth-Dreese et al. Blood 1995, vol. 85, pp. 2802-2812.
Cunningham et al. Journal of cell Science 1994, vol. 107, pp. 443-449.
Hargreaves et al. International Immunology 1995, vol. 7, pp. 1505-1513.
Hodge et al., “A Triad of Costimulatory Molecules Synergize to Amplify T-cell Activation”, Cancer Research, vol. 59, Nov. 15, 1999, pp. 5800-5807.
Hodge James
Panicali Dennis
Schlom Jeffrey
Heller Ehram White and McAuliffe
Housel James
Li Bao Qun
The United States of America as represented by the Department of
LandOfFree
Recombinant vector expressing multiple costimulatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant vector expressing multiple costimulatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant vector expressing multiple costimulatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3478140